there seems to be way more made of this issue than I had ever anticipated - and by more posters than need be - so here goes...
Warp makes some valid points, as do you and NT in your reply posts. Funding as we know is not static - its dynamic - and its fluid. It can come from various sources such as VC's, JV's, grants, endowments, private placements, etc. Dilution is not the only way.
Yes, LPC was and is a gift - and I never spoke about the "D" word after they were brougt to the table and signed with AMBS for a $20-Mil. SEDA. I personally had been on Gerald for at least 1 year to bring Josh Schienfeld and Dickie Vogel in - a select few here already know this story - and GC did - thank God. Yes, we have $2.4-Mil cash on hand which will get us to 1/1/15. Yes, we have an addit. $18.4-Mil. with LPC which as advertised, will get us well into FY16 - all well within the current 1-Bil AS count. Last I checked, we're currently at 768-Mil. in the float.
But we must also be cognizant that without a $35-$50-Mil. LymPro JV agreement up-front payment and continued studies required for both NuroPro, Eltroprazene and LymPro, these costs will get added to the monthly $700k burn and the expense accounts bottom line. Do we have a clear understanding of just how expensive it would be if GC & JC want to continuing keeping AMBS a "Walled Garden" and take these products to market alone, provided GC will not be low balled or bullied by a BP? It will be well north of the mere $18.4-Mil. that LPC will provide per there next few tranches. Once the new 1-Bil is authorized, they are authorized. Sure - newly dilutive shares can be used to spin off of the Diagnostic's Div. or for acquisitions. There are no set rules in play as to just how they will be used - and that has some on shaky grounds - understandably so. All that said, does anybody here know who exactly the financial advisors who are guiding AMBS - I would sure like to see any attempts to answer this....
Also, I don't question GC's ability to lead AMBS, but there is a marked difference between a 60 year old BioPharma CEO veteran and someone's 1st time ever as a CEO. Personally speaking, I think for 32 years of age, GC will eventually be looked upon as a gifted leader in this newly burgeoning field of Nurotrophic Factors, and will make quite possibly the annals of history - provided we hit on all 8 cylinders here with the product pipeline.
There is also something to be said about what we know collectively as die hard Longs and what the Street's knee jerk reactions are to information. Sell offs like we've had in Jan. after the LA Convention on the CPT Code issue and again in July at the UN Summit are highly indicative of just how powerful the Street is and how much money can be dropped in literally and hour or 2 - if spooked. And the Street was spooked both times - regardless of MoneyRunners or not. It took us 3 months to get to $0.195 and quite literally less than 3 hours in one afternoon to drop to $0.112 = 43% drop. GC could use some tutoring on Wall St. psychology is all I'm saying. I'm genuinely looking forward to the next few weeks after todays apparent retrace...
All the Best, JP
Warp makes some valid points, as do you and NT in your reply posts. Funding as we know is not static - its dynamic - and its fluid. It can come from various sources such as VC's, JV's, grants, endowments, private placements, etc. Dilution is not the only way.
Yes, LPC was and is a gift - and I never spoke about the "D" word after they were brougt to the table and signed with AMBS for a $20-Mil. SEDA. I personally had been on Gerald for at least 1 year to bring Josh Schienfeld and Dickie Vogel in - a select few here already know this story - and GC did - thank God. Yes, we have $2.4-Mil cash on hand which will get us to 1/1/15. Yes, we have an addit. $18.4-Mil. with LPC which as advertised, will get us well into FY16 - all well within the current 1-Bil AS count. Last I checked, we're currently at 768-Mil. in the float.
But we must also be cognizant that without a $35-$50-Mil. LymPro JV agreement up-front payment and continued studies required for both NuroPro, Eltroprazene and LymPro, these costs will get added to the monthly $700k burn and the expense accounts bottom line. Do we have a clear understanding of just how expensive it would be if GC & JC want to continuing keeping AMBS a "Walled Garden" and take these products to market alone, provided GC will not be low balled or bullied by a BP? It will be well north of the mere $18.4-Mil. that LPC will provide per there next few tranches. Once the new 1-Bil is authorized, they are authorized. Sure - newly dilutive shares can be used to spin off of the Diagnostic's Div. or for acquisitions. There are no set rules in play as to just how they will be used - and that has some on shaky grounds - understandably so. All that said, does anybody here know who exactly the financial advisors who are guiding AMBS - I would sure like to see any attempts to answer this....
Also, I don't question GC's ability to lead AMBS, but there is a marked difference between a 60 year old BioPharma CEO veteran and someone's 1st time ever as a CEO. Personally speaking, I think for 32 years of age, GC will eventually be looked upon as a gifted leader in this newly burgeoning field of Nurotrophic Factors, and will make quite possibly the annals of history - provided we hit on all 8 cylinders here with the product pipeline.
There is also something to be said about what we know collectively as die hard Longs and what the Street's knee jerk reactions are to information. Sell offs like we've had in Jan. after the LA Convention on the CPT Code issue and again in July at the UN Summit are highly indicative of just how powerful the Street is and how much money can be dropped in literally and hour or 2 - if spooked. And the Street was spooked both times - regardless of MoneyRunners or not. It took us 3 months to get to $0.195 and quite literally less than 3 hours in one afternoon to drop to $0.112 = 43% drop. GC could use some tutoring on Wall St. psychology is all I'm saying. I'm genuinely looking forward to the next few weeks after todays apparent retrace...
All the Best, JP
